Table 1.
Clinical and treatment parameters of the study population stratified by treatment cohort.
| Continuous Variables | Prostate only (n = 66) | Pelvis (n = 59) | All Patients (n = 125) | |||||
| Mean ± SD | Median | Mean ± SD | Median | p* | Mean ± SD | Median | ||
| Age at treatment (years) | 73.9 ± 7.8 | 75.5 | 73.9 ± 8.3 | 76.3 | 0.971 | 73.9 ± 8.0 | 75.8 | |
| Pre-treatment IPSS | 10.9 ± 7.0 | 10.0 | 11.8 ± 8.3 | 11.5 | 0.526 | 11.3 ± 7.6 | 10.0 | |
| Pre-treatment PSA (ng/mL) | 7.7 ± 5.3 | 6.5 | 29.6 ± 68.4 | 10.3 | 0.011 | 18.0 ± 48.0 | 7.3 | |
| Gleason Score | 6.5 ± 0.7 | 6. | 7.8 ± 1.2 | 8.0 | < 0.001 | 7.1 ± 1.2 | 7.0 | |
| % positive biopsies | 29.0 ± 23.7 | 18.5 | 62.3 ± 32.8 | 62.5 | < 0.001 | 44.2 ± 32.6 | 33.3 | |
| Prostate volume (cm3) | 54.8 ± 33.8 | 47.3 | 51.6 ± 33.2 | 42.0 | 0.597 | 53.3 ± 33.5 | 46.5 | |
| Post void residual (cc) | 57.3 ± 67.0 | 30.0 | 58.0 ± 88.0 | 27.0 | 0.961 | 57.6 ± 77.3 | 28.0 | |
| BMI | 27.8 ± 3.9 | 27.4 | 29.2 ± 5.0 | 28.5 | 0.950 | 28.4 ± 4.4 | 28.2 | |
| Categorical Variables | Count (%) | Count (%) | p∀ | Count (%) | ||||
| Stage (median) | T1b-T2b | 65 (98.5) | 46 (78.0) | < 0.001 | 111 (88.8) | |||
| ≥ T2c | 1 (1.5) | 13 (22.0) | 14 (11.2) | |||||
| ADT | none | 55 (83.3) | 19 (32.2) | < 0.001 | 74 (59.2) | |||
| ≤ 6 months | 7 (10.6) | 2 (3.4) | 9 (7.2) | |||||
| > 6 months | 4 (6.1) | 38 (64.4) | 42 (33.6) | |||||
| Diabetes | 11 (16.9) | 14 (23.7) | 0.236 | 25 (20.0) | ||||
| Hypertension | 43 (65.2) | 39 (66.1) | 0.531 | 82 (65.6) | ||||
| Alpha blocker | 53 (80.3) | 43 (72.9) | 0.221 | 96 (76.8) | ||||
| Perineural invasion | 13 (19.7) | 28 (47.5) | 0.001 | 41 (32.8) | ||||
* p values calculated by one-way ANOVA
∀ p values determined by 2-sided Fisher's Exact Test